We are live on ! Find out more
SCM

Sarissa Capital Management Portfolio holdings

AUM $158M
1-Year Est. Return 103.7%
This Fund
S&P 500
This Quarter Est. Return
+25.25%
1 Year Est. Return
+103.7%
3 Year Est. Return
+58.62%
5 Year Est. Return
+92.85%
10 Year Est. Return
+667.68%
AUM
$980M
AUM Growth
+$130M
Cap. Flow
-$10.6M
Cap. Flow %
-1.08%
Top 10 Hldgs %
99.98%
Holding
12
New
1
Increased
3
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$17.1M
2
SRSAW
Sarissa Capital Acquisition Corp. Warrants
SRSAW
+$7.79M
3
ALKS icon
Alkermes
ALKS
+$2.29M
4
MRSN
Mersana Therapeutics
MRSN
+$2M

Top Sells

Rank Stock Value
1
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$39.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IRWD icon
1
Ironwood Pharmaceuticals
IRWD
$635M
$160M 16.32%
14,040,000
– –
ALKS icon
2
Alkermes
ALKS
$8.79B
$159M 16.19%
7,950,000
+125,000
+2% +$2.29M
BIIB icon
3
Biogen
BIIB
$30.4B
$157M 16.07%
643,000
– –
JAZZ icon
4
Jazz Pharmaceuticals
JAZZ
$15.5B
$153M 15.63%
928,100
– –
ALXN
5
DELISTED
Alexion Pharmaceuticals
ALXN
$125M 12.72%
797,740
– –
INVA icon
6
Innoviva
INVA
$1.6B
$79.5M 8.11%
6,414,000
– –
MRSN
7
DELISTED
Mersana Therapeutics
MRSN
$77.9M 7.95%
117,080
+3,600
+3% +$2M
BCRX icon
8
BioCryst Pharmaceuticals
BCRX
$2.36B
$60.9M 6.22%
8,175,000
+3,314,000
+68% +$17.1M
SRSAW
9
DELISTED
Sarissa Capital Acquisition Corp. Warrants
SRSAW
$5M 0.51%
+3,333,333
New +$7.79M
RGLS
10
DELISTED
Regulus Therapeutics
RGLS
$2.5M 0.26%
185,185
– –
MRTX
11
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$219K 0.02%
1,000
– –
ICPT
12
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$23K ﹤0.01%
950
-1,200,050
-100% -$39.8M

Similar funds

DWA
Dougherty Wealth Advisers Wayzata, Minnesota $158M AUM 18.41% 1-Year Est. Return
4A
4D Advisors Redondo Beach, California $158M AUM 92.73% 1-Year Est. Return
DAM
Deepwater Asset Management Minneapolis, Minnesota $158M AUM 23.9% 1-Year Est. Return
PCP
Pantera Capital Partners San Francisco, California $158M AUM 600.89% 1-Year Est. Return
RA
RiverTree Advisors Winter Park, Florida $158M AUM 5.18% 1-Year Est. Return
FI
FWG Investments Lexington, Kentucky $157M AUM 15.2% 1-Year Est. Return
CC
Corsicana & Co Corsicana, Texas $158M AUM
PWA
Providence Wealth Advisors Frankfort, Illinois $157M AUM 29.27% 1-Year Est. Return

Sarissa Capital Management's Q4 2020 Portfolio in Review

As of Q4 2020, Sarissa Capital Management held 12 positions worth $980M, up 15% from $849M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Sarissa Capital Management's Q4 2020 filing shows 1 new, 3 increased and 1 reduced positions. Its largest new stake was Sarissa Capital Acquisition Corp. Warrants: 3,333,333 shares worth $5M. The largest sale was Intercept Pharmaceuticals, Inc., an estimated $39.8M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier.

  • Sarissa Capital Management's largest Q4 2020 buy was Sarissa Capital Acquisition Corp. Warrants: 3,333,333 shares worth $5M.
  • Sarissa Capital Management added most to BioCryst Pharmaceuticals in Q4 2020, an estimated $17.1M increase.
  • Sarissa Capital Management's biggest Q4 2020 reduction was Intercept Pharmaceuticals, Inc., cutting an estimated $39.8M.
  • Sarissa Capital Management's ten largest holdings make up 100% of its $980M portfolio in Q4 2020.
  • Sarissa Capital Management opened 1 new position and closed 0 in Q4 2020.
  • Sarissa Capital Management's portfolio value rose 15% quarter-over-quarter to $980M.

Based on Sarissa Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.